Table 3.

Patient demographic and clinical results, by APOE ɛ4 allele carrier status

Characteristic	APOE ɛ4 non-carriers	APOE ɛ4 carriers	p
No. of participants	67	33	-
Gender: Males, No. (%)	48 (71.6)	24 (72.7)	0.90*
Disease duration, mean (range), y	3.585 (1–13)	2.909 (1–6)	0.147
Age at symptom onset, mean [SD] (range), y	69.30 [7.79](44–85)	70.75 [5.71](62–80)	0.274
Age at testing, mean [SD] (range), y	72.79 [7.47](57–89)	73.74 [5.78](65–83)	0.31
Educational level, mean [SD], y	14.32 [4.01]	15.66 [3.37]	0.428
RBDQ score, mean [SD]	5.51 [3.24]	5.64 [3.2]	0.464
Hallucinations, No. (%)	46 (70.7)	21 (67.74)	0.763*
AChEI, No. (%)	40 (62.5)	18 (54.54)	0.449*
MMSE [SD]. N = 94	23.03 [6.01]	24 [4.85]	0.72**
MoCA [SD]. N = 86	18.36 [5.8]	19.07 [5.61]	0.733**
UPDRS motor part 3 [SD]. N = 93	31.48 [11.87]	27.81 [12.73]	0.82+
Difference in MMSE 1 year to baseline, mean [SD]. N = 34	–1.20 [3.90]	–1.22[3.27]	0.809*
Difference in MMSE 2 years to baseline, mean [SD]. N = 23	–3.14 [5.53]	–1.44 [2.55]	0.689*

All p-values reflect two-tailed t-test results unless marked with an asterisk; ^*p-values obtained by chi-squared test; ^**p-values obtained by ANCOVA with age, disease duration, and ACEI use as covariates; ⁺p-values obtained by ANCOVA with age and disease duration as covariates. MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; UPDRS, Unified Parkinson Disease Rating Scale; RBDQ, REM sleep behavior disorder questionnaire; AChEI, acetylcholine esterase inhibitors.